Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street dips as spiking crude prices revive fears of inflation, rate hike
- The Warsh pivot markets didn't expect
- Oil rises over 2% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)
August 23, 2024 7:50 AM EDTBrookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $310.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Conclusions Todays announcement that FDA has approved Modernas new formulation for its COVID-19 vaccine (2024-2025 formulation) targeting the KP.2 variant of SARS-CoV-2, the variant based on guidance from the FDA. This approval follows a... More
